Topics Presented this February 2018 at RNA Therapeutics
Want to learn about exploiting exosomes for therapeutic use in patients with cystic fibrosis?
Have questions answered during our two sessions presented by ProQR Therapeutics and University of Oxford.
Exploiting Exosomes for Therapeutic and Diagnostic Applications | Day 2 | @16:40
This presentation will examine the translational applications of exosome research, including biomarker discovery and drug delivery. The session will consider and evaluate of the important advantages compared to other nanoparticulate drug delivery systems and look at ways of overcoming potential problems with component characterization and immune reactions.
Presented by: Samir EL Andaloussi, Assistant Professor, Karolinska Institutet and Research Fellow, University of Oxford
RNA Therapeutics for Patients with Cystic Fibrosis: QR-010 and Beyond | Day 1 | @11:00
This session will explore the opportunities that RNA therapeutics may bring for patients with cystic fibrosis. The evidence for QR-010 as a meaningful RNA therapeutic for patients with cystic fibrosis will be discussed, looking specifically at the F508del mutation. Other mutations will also be explored while looking at RNA therapeutic approaches for patients with cystic fibrosis.
Presented by: Noreen Roth Henig, Chief Medical Officer, ProQR Therapeutics
- Hear from MiNA Therapeutics about their new pre-clinical data supporting the on-target mechanism of action of their pioneering new drug candidate MTL-CEBPA.
- Learn how CureVac’s sophisticated technologies and approaches have helped overcome limitations such as the instability of single-stranded RNA.
- Discover STORM Therapeutics’ innovative approach: Harnessing the power of RNA epigenetics to develop first-inclass drugs in oncology.
- Expand knowledge of patenting RNA Therapeutics, with James Ogle, a European and UK Chartered Patent Attorney with particular expertise in RNA and other nucleic acidbased technologies.
- Examine the latest developments in delivery systems for RNA Therapeutics, including Exosomes, Nanocomplexes and Platform Delivery Approaches.
For those looking to attend there is currently a £200 early-bird saving, ending November 30th.
Further information is available at: www.therapeutics-rna.com/opr
SMi presents the 9th Annual Conference:
Date: 21st – 22nd February 2018
Location: Holiday Inn London - Kensington Forum
Sponsored by: ChemGenes | Phion Therapeutics
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: email@example.com
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Topics Presented this February 2018 at RNA Therapeutics here
News-ID: 824116 • Views: 546
More Releases from SMi Group
Sponsor Boeing Presentation Released for the Virtual Military Airlift and Air-to …
SMi Group Reports: Senior representatives from Boeing are set to give a joint presentation at the Military Airlift and Air-to-Air Refuelling Conference in December Delegates at this year’s Military Airlift and Air-to-Air Refuelling Conference, taking place virtually on the 1st-2nd December 2020, will have the opportunity to schedule meetings with sponsors and visit sponsor exhibition stands throughout the day. All attendance by military and government personnel will be free of charge
Exclusive interview released with CJOS COE ahead of the virtual Maritime Reconna …
SMi Group reports: A senior representative from the Combined Joint Operations from the Sea Centre of Excellence (CJOS COE) is speaking at the virtual event next February. Ahead of SMi Group’s Maritime Reconnaissance and Surveillance Technology conference, taking place virtually on the 3rd and 4th February 2021, a speaker interview has been released with Commodore Thomas Guy, Deputy Director, CJOS COE to discuss his role, current priorities, opportunities and the
Border Security 2021 turns into a Virtual Conference
SMi Group reports: The Border Security conference taking place next February will no longer take place in Prague and will now be a virtual event. In light of on-going developments with COVID-19, SMi Group have decided to move its 14th annual Border Security conference, taking place on the 10th-11th February 2021, to a fully online, virtual experience. SMi Group’s virtual conference platform will enable attendees to: • Create their own virtual profile • Connect with
Boeing sign up to sponsor the Virtual Military Airlift and Air-to-Air Refuelling …
SMi Group Reports: Boeing is the latest sponsor to confirm their attendance at the Military Airlift and Air-to-Air Refuelling Conference in December SMi Group are delighted to announce Boeing have now signed up to sponsor, speak and exhibit at the virtual 21st Annual Military Airlift and Air-to-Air Refuelling Conference, taking place on the 1st-2nd December 2020. Boeing is the world's largest aerospace company and leading manufacturer of defense, space and security
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
Automated DNA/RNA Isolation System Market Overview Till 2018-2023
Future Market Reports on Global Automated DNA/RNA Isolation System 2018 Research Report presents a professional and complete analysis of on the current Industry situation. The Global report includes Automated DNA/RNA Isolation System Revenue, market Share, industry volume, Trends, Growth aspects. It analyses the important factors of the based on present industry situations, demands, business strategies utilized by Automated DNA/RNA Isolation System market players and the future prospects from various angles
RNA Sequencing: Technologies and Analyses of Global Market Trends
"The Latest Research Report RNA Sequencing: Technologies and Global Markets provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The global RNA-Sequencing market reached nearly $1.1 billion in 2015, and should reach $1.2 billion in 2016 and $2.1 billion in 2020, registering a compound annual growth rate (CAGR) of 14.9%. The tools and reagents segment should reach over $1.0 billion in 2020 from $566.8
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and